Risk factors of cytomegalovirus infection in patients after allogeneic hematopoietic stem cells transplantation
Abstract
Cytomegalovirus infection (CMV) is an extremely serious problem in patients after hematopoietic stem cells transplantation (HSCT). We have evaluated importance of major risk factors CMV development in patients after allogeneic HSCT (n = 168) from related (n = 56), unrelated (n = 90) or haploidentical donors (n = 22). Clinical importance of HSCT type as risk factors CMV development was shown; patients after unrelated or haploidentical HSCT had the worst prognosis. We also demonstrated that ≥ 2 grade acute GVHD statistically significant increase CMV reactivation probability after any types of HSCT. Comparison of infection reactivation frequency and event-free survival between subgroups of patients, received HSCT from CMV-positive and CMV-negative donors, absence of any differences was revealed. In the second group CMV infection was more severe. Preventive gancyclovir treatment has not shown efficacy and any influence on frequency of CMV reactivation.
About the Authors
D. N. BalashovRussian Federation
Moscow
P. E. Trakhtman
Russian Federation
Moscow
E. V. Skorobogatova
Russian Federation
Moscow
Yu. V. Skvortsova
Russian Federation
Moscow
I. P. Schipitsyna
Russian Federation
Moscow
A. A. Maschan
Russian Federation
Moscow
References
1. Stocchi R., Ward K. N., Fanin R., Baccarani M., Apperley J. F. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica 1998; 84: 71–9.
2. Taylor-Wiedeman J., Sissons J. G., Borysiewicz L. K., Sinclair J. H. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991; 72: 2059–64.
3. Soderberg-Naucler C., Fish K. N., Nelson J. A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91: 119–26.
4. Michelson S. Interaction of human CMV with monocytes / macrophages: a love-hate relationship. Pathol Biol Paris 1997; 45: 146–58.
5. Boeckh M., Nichols W. G., Papanicolaou G. et al. Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients: Current Status, Known Challenges, and Future Strategies. Biology of Blood and Marrow Transplantation 2003; 9: 543–58.
Review
For citations:
Balashov D.N., Trakhtman P.E., Skorobogatova E.V., Skvortsova Yu.V., Schipitsyna I.P., Maschan A.A. Risk factors of cytomegalovirus infection in patients after allogeneic hematopoietic stem cells transplantation. Oncohematology. 2010;(4):20-26. (In Russ.)